A list of nonpreferred brand-name drugs and their preferred alternatives developed by an independent group of clinical pharmacists and doctors. The group evaluates drugs within therapeutic classes. Where two or more drugs are considered therapeutically equivalent (produce the same results), the committee will select the most economically advantageous alternative to be classified as the preferred brand-name drug.